You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxybutynin
Accession NumberDB01062  (APRD00427)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionOxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
Structure
Thumb
Synonyms
4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
Oxibutinina
Oxybutynin
Oxybutynine
Oxybutyninum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Albert OxybutyninTablet5 mgOralAventis Pharma Inc1996-11-212002-07-29Canada
Ava-oxybutyninTablet5 mgOralAvanstra Inc2011-08-222014-08-21Canada
Ditropan Syrup 1mg/mlSyrup1 mgOralJanssen Inc1993-12-312007-02-21Canada
Ditropan Tablets 5mgTablet5 mgOralJanssen Inc1993-12-312006-08-04Canada
Ditropan XLTablet, extended release15 mg/1OralJanssen Pharmaceuticals, Inc.1999-06-26Not applicableUs
Ditropan XLTablet, extended release10 mg/1OralPhysicians Total Care, Inc.2003-06-23Not applicableUs
Ditropan XLTablet, extended release15 mg/1OralPhysicians Total Care, Inc.2003-06-25Not applicableUs
Ditropan XLTablet, extended release5 mg/1OralJanssen Pharmaceuticals, Inc.1999-06-26Not applicableUs
Ditropan XLTablet, extended release15 mgOralJanssen IncNot applicableNot applicableCanada
Ditropan XLTablet, extended release10 mg/1OralJanssen Pharmaceuticals, Inc.1999-06-26Not applicableUs
Ditropan XL -(10mg)Tablet, extended release10 mgOralJanssen Inc2001-06-22Not applicableCanada
Ditropan XL -(5mg)Tablet, extended release5 mgOralJanssen Inc2001-06-22Not applicableCanada
Dom-oxybutynin 5 Mg TabletsTablet5 mgOralDominion Pharmacal1999-12-16Not applicableCanada
GelniqueGel100 mgTopicalWatson Laboratories IncNot applicableNot applicableCanada
GelniqueGel28 mg/.92gTransdermalActavis Pharma, Inc.2012-04-02Not applicableUs
GelniqueGel100 mg/gTransdermalActavis Pharma, Inc.2009-05-15Not applicableUs
GelniqueGel100 mgTopicalAllergan Pharma Co.2011-10-27Not applicableCanada
GelniqueGel100 mg/gTransdermalPhysicians Total Care, Inc.2010-09-15Not applicableUs
KenteraGel90.7 mg/gTransdermalNicobrand Ltd.2004-06-15Not applicableEu
KenteraGel90.7 mg/gTransdermalNicobrand Ltd.2004-06-15Not applicableEu
KenteraPatch3.9 mg/24hTransdermalNicobrand Ltd.2004-06-15Not applicableEu
KenteraPatch3.9 mg/24hTransdermalNicobrand Ltd.2004-06-15Not applicableEu
KenteraPatch3.9 mg/24hTransdermalNicobrand Ltd.2004-06-15Not applicableEu
Mylan-oxybutyninTablet5 mgOralMylan Pharmaceuticals Ulc1997-04-242016-06-28Canada
Ntp-oxybutyninTablet5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-oxybutynSyrup1 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-oxybutyn - Tab 5mgTablet5 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Oxybutyn - 5mgTablet5 mgOralValeant Canada Lp/valeant Canada s.e.c.1996-10-312016-07-08Canada
OxybutyninTablet5 mgOralSanis Health Inc2010-05-12Not applicableCanada
Oxybutynin ChlorideTablet, extended release15 mg/1OralMylan Pharmaceuticals Inc.2007-05-10Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralPatriot Pharmaceuticals, LLC1999-06-26Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-05-10Not applicableUs
Oxybutynin ChlorideTablet, extended release5 mg/1OralPatriot Pharmaceuticals, LLC1999-06-26Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralPatriot Pharmaceuticals, LLC1999-06-26Not applicableUs
Oxybutynine-5 - Tab 5mgTablet5 mgOralPro Doc Limitee1996-12-06Not applicableCanada
OxytrolPatch3.9 mg/dTransdermalActavis Pharma, Inc.2003-02-26Not applicableUs
OxytrolPatch36 mgTransdermalAllergan Pharma Co.2004-08-12Not applicableCanada
Pat-oxybutynin Chloride ERTablet, extended release15 mgOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-oxybutynin Chloride ERTablet, extended release5 mgOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-oxybutynin Chloride ERTablet, extended release10 mgOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Penta-oxybutynin Chloride TabletsTablet5 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PHL-oxybutyninTablet2.5 mgOralPharmel Inc2004-12-02Not applicableCanada
PHL-oxybutyninSyrup1 mgOralPharmel Inc2004-12-06Not applicableCanada
PHL-oxybutyninTablet5 mgOralPharmel Inc2002-05-29Not applicableCanada
PMS-oxybutyninSyrup1 mgOralPharmascience Inc1996-09-04Not applicableCanada
PMS-oxybutyninTablet2.5 mgOralPharmascience Inc1999-11-22Not applicableCanada
PMS-oxybutyninTablet5 mgOralPharmascience Inc1999-11-22Not applicableCanada
Riva-oxybutyninTablet5 mgOralLaboratoire Riva Inc2000-05-052013-07-31Canada
Riva-oxybutyninTablet5 mgOralLaboratoire Riva Inc2008-06-09Not applicableCanada
Teva-oxybutyninTablet5 mgOralTeva Canada Limited1997-02-28Not applicableCanada
UromaxTablet, extended release10 mgOralPurdue Pharma2006-05-152013-08-01Canada
UromaxTablet, extended release15 mgOralPurdue Pharma2006-05-152013-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxybutyninSyrup1 mgOralApotex Inc1997-04-28Not applicableCanada
Apo-oxybutynin - Tab 5mgTablet5 mgOralApotex Inc1995-12-31Not applicableCanada
Oxybutynin ChlorideTablet5 mg/1OralUpsher Smith Laboratories, Inc.2011-11-07Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralPhysicians Total Care, Inc.2010-01-13Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1Oralbryant ranch prepack2007-05-11Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-11-10Not applicableUs
Oxybutynin ChlorideTablet, extended release5 mg/1OralAv Kare, Inc.2016-01-082016-03-18Us
Oxybutynin ChlorideSolution5 mg/5mLOralQualitest Pharmaceuticals2004-12-282018-01-31Us
Oxybutynin ChlorideTablet, extended release5 mg/1OralTeva Pharmaceuticals USA Inc2007-05-11Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralCardinal Health1997-10-31Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralA S Medication Solutions1997-10-31Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralAccord Healthcare, Inc.2016-10-10Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralCardinal Health2011-11-07Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralAmneal Pharmaceuticals of New York, LLC2015-11-02Not applicableUs
Oxybutynin ChlorideTablet, extended release5 mg/1OralCarilion Materials Management2007-05-11Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralAvera Mc Kennan Hospital2015-03-10Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralRebel Distributors Corp.1997-10-31Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralMylan Institutional Inc.2006-11-27Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralPhysicians Total Care, Inc.2006-12-11Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralMylan Pharmaceuticals Inc.2006-11-10Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralMc Kesson Contract Packaging2011-09-19Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralA S Medication Solutions1990-09-30Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralKAISER FOUNDATION HOSPITALS2015-10-14Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2009-03-01Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralCardinal Health2004-02-03Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-11-10Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralAv Kare, Inc.2016-01-082016-03-18Us
Oxybutynin ChlorideTablet, extended release5 mg/1OralMajor Pharmaceuticals2015-11-02Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralTeva Pharmaceuticals USA Inc2007-05-11Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Oxybutynin ChlorideSyrup5 mg/5mLOralMorton Grove Pharmaceuticals, Inc.1997-02-12Not applicableUs
Oxybutynin ChlorideTablet, extended release5 mg/1OralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Oxybutynin ChlorideSolution5 mg/5mLOralAtlantic Biologicals Corps2004-12-28Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralMylan Institutional Inc.2006-11-27Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralCardinal Health2006-11-10Not applicableUs
Oxybutynin ChlorideTablet, extended release5 mg/1OralDispensing Solutions, Inc.2007-05-11Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralREMEDYREPACK INC.2016-02-24Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralREMEDYREPACK INC.2013-04-052016-10-26Us
Oxybutynin ChlorideTablet5 mg/1OralQualitest Pharmaceuticals1997-10-31Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralREMEDYREPACK INC.2011-09-292016-11-08Us
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralPhysicians Total Care, Inc.2006-12-12Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralMylan Pharmaceuticals Inc.2006-11-10Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralCardinal Health2010-07-282015-12-29Us
Oxybutynin ChlorideTablet5 mg/1OralPreferred Pharmaceuticals Inc.2016-06-09Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralA S Medication Solutions1997-10-31Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralBlenheim Pharmacal, Inc.2013-10-02Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralCardinal Health1997-10-312016-02-25Us
Oxybutynin ChlorideTablet, extended release5 mg/1OralAmneal Pharmaceuticals of New York, LLC2015-11-02Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralREMEDYREPACK INC.2013-05-29Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralSt Marys Medical Park Pharmacy2013-05-16Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralMc Kesson Contract Packaging2011-12-23Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralAphena Pharma Solutions Tennessee, Llc2011-11-07Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralTeva Pharmaceuticals USA Inc2006-11-10Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.1997-10-31Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralAidarex Pharmaceuticals LLC1997-10-31Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralREMEDYREPACK INC.2013-02-252016-10-13Us
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralCardinal Health2013-05-20Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralAmerican Health Packaging2010-01-13Not applicableUs
Oxybutynin ChlorideTablet, extended release5 mg/1OralAccord Healthcare, Inc.2016-10-10Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-10-30Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralPliva Inc.1990-09-30Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralPhysicians Total Care, Inc.2007-01-08Not applicableUs
Oxybutynin ChlorideTablet5 mg/1Oralbryant ranch prepack1997-10-31Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release15 mg/1OralMylan Pharmaceuticals Inc.2006-11-10Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralCardinal Health2010-07-282015-12-29Us
Oxybutynin ChlorideTablet5 mg/1OralProficient Rx LP1990-09-30Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralCardinal Health2011-05-20Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralAmneal Pharmaceuticals of New York, LLC2015-11-02Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralCardinal Health2010-01-13Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralUnit Dose Services1990-09-30Not applicableUs
Oxybutynin ChlorideSyrup5 mg/5mLOralSilarx Pharmaceuticals, Inc2009-09-08Not applicableUs
Oxybutynin ChlorideTablet, extended release15 mg/1OralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release5 mg/1OralMc Kesson Contract Packaging2011-10-12Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralA S Medication Solutions2011-11-07Not applicableUs
Oxybutynin ChlorideSyrup5 mg/5mLOralPharmaceutical Associates, Inc.1998-12-18Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralAphena Pharma Solutions Tennessee, Llc1997-10-31Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-05-11Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralCardinal Health2006-11-10Not applicableUs
Oxybutynin ChlorideTablet, extended release10 mg/1OralAccord Healthcare, Inc.2016-10-10Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release5 mg/1OralAv Pak2012-05-17Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release10 mg/1OralAmerican Health Packaging2012-08-31Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release10 mg/1OralRising Pharmaceuticals, Inc.2016-09-27Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release10 mg/1OralKremers Urban Pharmaceuticals Inc.2009-03-01Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release10 mg/1OralAv Pak2012-05-17Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release5 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-05-18Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-03-01Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release5 mg/1OralAv Kare, Inc.2016-03-09Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release15 mg/1OralRising Pharmaceuticals, Inc.2016-09-27Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release15 mg/1OralKremers Urban Pharmaceuticals Inc.2009-03-01Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release15 mg/1OralAv Pak2012-05-16Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release10 mg/1OralAv Kare, Inc.2016-03-09Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release5 mg/1OralRising Pharmaceuticals, Inc.2016-09-27Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release5 mg/1OralKremers Urban Pharmaceuticals Inc.2009-03-01Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release5 mg/1OralAmerican Health Packaging2012-01-10Not applicableUs
Oxybutynin Chloride Extended ReleaseTablet, extended release15 mg/1OralAv Kare, Inc.2016-03-09Not applicableUs
Oxybutynin Chlorideextended Release Extended ReleaseTablet, extended release10 mg/1OralREMEDYREPACK INC.2013-09-19Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxytrol for WomenPatch3.9 mg/dTransdermalMSD Consumer Care, Inc.2013-08-19Not applicableUs
Oxytrol for WomenPatch3.9 mg/dTransdermalMSD Consumer Care, Inc.2013-08-19Not applicableUs
Oxytrol for WomenPatch3.9 mg/dTransdermalActavis Pharma, Inc.2016-01-01Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
DitropanNot Available
LenditroNot Available
Lyrinel XLNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxybutynin Chloride
Thumb
  • InChI Key: SWIJYDAEGSIQPZ-UHFFFAOYNA-N
  • Monoisotopic Mass: 393.207071602
  • Average Mass: 393.947
DBSALT000430
Categories
UNIIK9P6MC7092
CAS number5633-20-5
WeightAverage: 357.4864
Monoisotopic: 357.230393863
Chemical FormulaC22H31NO3
InChI KeyXIQVNETUBQGFHX-UHFFFAOYSA-N
InChI
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
IUPAC Name
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
SMILES
CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of overactive bladder.
Structured Indications
PharmacodynamicsOxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.
Mechanism of actionOxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M3Proteinyes
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M2Proteinyes
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Related Articles
AbsorptionRapidly absorbed from gastrointestinal tract.
Volume of distribution
  • 193 L
Protein binding91%-93%
Metabolism

Hepatic, primarily by CYP3A4

SubstrateEnzymesProduct
Oxybutynin
N-desethyloxybutyninDetails
Route of eliminationOxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Half life12.4-13.2 hours
Clearance

Estimated to be 26L/h.

ToxicityLD50=1220 mg/kg (Orally in rats, Goldenthal)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Oxybutynin.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ambenonium.Approved
AmiodaroneThe serum concentration of Oxybutynin can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Oxybutynin.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxybutynin.Approved
AprepitantThe serum concentration of Oxybutynin can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Oxybutynin.Approved, Investigational
AtazanavirThe serum concentration of Oxybutynin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Oxybutynin can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxybutynin.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxybutynin.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxybutynin.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxybutynin.Approved
BexaroteneThe serum concentration of Oxybutynin can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxybutynin.Approved
BoceprevirThe serum concentration of Oxybutynin can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Oxybutynin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Oxybutynin can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Oxybutynin can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Carfentanil.Illicit, Vet Approved
CeritinibThe serum concentration of Oxybutynin can be increased when it is combined with Ceritinib.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Oxybutynin.Approved
CimetropiumOxybutynin may increase the anticholinergic activities of Cimetropium.Experimental
ClarithromycinThe serum concentration of Oxybutynin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Oxybutynin can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Oxybutynin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Oxybutynin can be increased when it is combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Oxybutynin can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe metabolism of Oxybutynin can be decreased when combined with Crizotinib.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxybutynin.Approved
CyclosporineThe metabolism of Oxybutynin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxybutynin.Approved, Investigational
DarunavirThe serum concentration of Oxybutynin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Oxybutynin can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Oxybutynin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Oxybutynin can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybutynin.Approved, Investigational
DexamethasoneThe serum concentration of Oxybutynin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Oxybutynin can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Oxybutynin can be decreased when combined with Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Donepezil.Approved
DoxycyclineThe metabolism of Oxybutynin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxybutynin is combined with DPDPE.Investigational
DronabinolOxybutynin may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Oxybutynin can be decreased when combined with Dronedarone.Approved
EchothiophateThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe serum concentration of Oxybutynin can be decreased when it is combined with Efavirenz.Approved, Investigational
EluxadolineOxybutynin may increase the constipating activities of Eluxadoline.Approved
EnzalutamideThe serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Oxybutynin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Oxybutynin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxybutynin.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Oxybutynin can be decreased when it is combined with Etravirine.Approved
FentanylThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxybutynin.Approved
FluconazoleThe metabolism of Oxybutynin can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Oxybutynin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Oxybutynin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Oxybutynin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Oxybutynin can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Oxybutynin can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxybutynin.Approved
Ginkgo bilobaThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Glucagon recombinant.Approved
GlycopyrroniumOxybutynin may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxybutynin.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxybutynin.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxybutynin.Approved
IdelalisibThe serum concentration of Oxybutynin can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Oxybutynin can be decreased when combined with Imatinib.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Oxybutynin.Approved
IndinavirThe serum concentration of Oxybutynin can be increased when it is combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxybutynin.Approved
IsavuconazoniumThe metabolism of Oxybutynin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsradipineThe metabolism of Oxybutynin can be decreased when combined with Isradipine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Oxybutynin.Investigational
ItraconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Oxybutynin can be increased when it is combined with Ivacaftor.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Ketoconazole.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Oxybutynin can be increased when it is combined with Lopinavir.Approved
LovastatinThe metabolism of Oxybutynin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Oxybutynin can be increased when combined with Lumacaftor.Approved
MalathionThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.Approved
MefloquineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxybutynin.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.Approved
MetixeneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Oxybutynin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Oxybutynin.Approved, Investigational
MianserinMianserin may increase the anticholinergic activities of Oxybutynin.Approved
MifepristoneThe serum concentration of Oxybutynin can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Mirabegron.Approved
MitotaneThe serum concentration of Oxybutynin can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Oxybutynin can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneOxybutynin may increase the tachycardic activities of Nabilone.Approved, Investigational
NafcillinThe serum concentration of Oxybutynin can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Nalbuphine.Approved
NefazodoneThe serum concentration of Oxybutynin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Oxybutynin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Oxybutynin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Oxybutynin can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Oxybutynin can be decreased when combined with Nilotinib.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Oxybutynin is combined with NVA237.Investigational
OlaparibThe metabolism of Oxybutynin can be decreased when combined with Olaparib.Approved
OpiumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Oxybutynin can be increased when it is combined with Osimertinib.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxybutynin.Approved
PalbociclibThe serum concentration of Oxybutynin can be increased when it is combined with Palbociclib.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pancuronium.Approved
PentazocineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Oxybutynin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Oxybutynin can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Oxybutynin can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.Approved
PiritramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Oxybutynin.Approved
PosaconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideOxybutynin may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Oxybutynin.Approved, Investigational
PrimidoneThe metabolism of Oxybutynin can be increased when combined with Primidone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxybutynin.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxybutynin.Approved
PropiverineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Oxybutynin.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxybutynin.Approved
RamosetronOxybutynin may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Oxybutynin can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Remifentanil.Approved
RifabutinThe metabolism of Oxybutynin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Oxybutynin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Oxybutynin can be increased when combined with Rifapentine.Approved
RitonavirThe serum concentration of Oxybutynin can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Rivastigmine.Approved, Investigational
SaquinavirThe serum concentration of Oxybutynin can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin.Approved, Investigational
SildenafilThe metabolism of Oxybutynin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Oxybutynin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Oxybutynin can be increased when it is combined with Simeprevir.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Solifenacin.Approved
St. John's WortThe serum concentration of Oxybutynin can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Oxybutynin can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Oxybutynin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxybutynin.Approved
TacrineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tapentadol.Approved
TelaprevirThe serum concentration of Oxybutynin can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Oxybutynin can be increased when it is combined with Telithromycin.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Oxybutynin.Approved
TiclopidineThe metabolism of Oxybutynin can be decreased when combined with Ticlopidine.Approved
TiotropiumOxybutynin may increase the anticholinergic activities of Tiotropium.Approved
TocilizumabThe serum concentration of Oxybutynin can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxybutynin.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxybutynin.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxybutynin.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimethaphan.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxybutynin.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxybutynin.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Oxybutynin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Vecuronium.Approved
VenlafaxineThe metabolism of Oxybutynin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Oxybutynin can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Oxybutynin can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Take with food.
References
Synthesis Reference

Masakatsu Shibasaki, “Method of producing oxybutynin and its derivatives.” U.S. Patent US20040006243, issued January 08, 2004.

US20040006243
General References
  1. Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6. [PubMed:16924061 ]
  2. Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8. [PubMed:17057269 ]
  3. Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5. [PubMed:17438194 ]
External Links
ATC CodesG04BD04
AHFS Codes
  • 86:12.00
PDB EntriesNot Available
FDA labelDownload (144 KB)
MSDSDownload (73 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9225
Blood Brain Barrier+0.9418
Caco-2 permeable+0.5989
P-glycoprotein substrateSubstrate0.7244
P-glycoprotein inhibitor IInhibitor0.6809
P-glycoprotein inhibitor IIInhibitor0.7244
Renal organic cation transporterNon-inhibitor0.558
CYP450 2C9 substrateNon-substrate0.812
CYP450 2D6 substrateNon-substrate0.7985
CYP450 3A4 substrateNon-substrate0.5213
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7137
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7038
BiodegradationNot ready biodegradable0.9878
Rat acute toxicity2.9059 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9548
hERG inhibition (predictor II)Inhibitor0.7337
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral5 mg
GelTopical100 mg
GelTransdermal100 mg/g
GelTransdermal28 mg/.92g
GelTransdermal90.7 mg/g
PatchTransdermal3.9 mg/24h
SolutionOral5 mg/5mL
SyrupOral5 mg/5mL
TabletOral5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral15 mg/1
Tablet, extended releaseOral5 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral5 mg/1
PatchTransdermal36 mg
PatchTransdermal3.9 mg/d
SyrupOral1 mg
TabletOral2.5 mg
Tablet, extended releaseOral15 mg
Prices
Unit descriptionCostUnit
Oxybutynin chloride powder54.47USD g
Oxytrol 3.9 mg/24hr Patches20.87USD patch
Oxytrol 3.9 mg/24hr patch20.06USD patch
Gelnique 10% gel sachets5.17USD g
Ditropan XL 15 mg 24 Hour tablet4.59USD tablet
Ditropan XL 10 mg 24 Hour tablet4.47USD tablet
Ditropan XL 5 mg 24 Hour tablet4.47USD tablet
Ditropan xl 15 mg tablet4.23USD tablet
Ditropan xl 10 mg tablet4.13USD tablet
Ditropan xl 5 mg tablet4.13USD tablet
Ditropan xl 5 mg tablet sa4.13USD tablet
Oxybutynin Chloride 15 mg 24 Hour tablet3.5USD tablet
Oxybutynin Chloride 10 mg 24 Hour tablet3.42USD tablet
Oxybutynin Chloride 5 mg 24 Hour tablet3.2USD tablet
Ditropan 5 mg tablet1.15USD tablet
Oxybutynin Chloride 5 mg tablet0.57USD tablet
Ditropan 5 mg/5ml Syrup0.26USD ml
Apo-Oxybutynin 5 mg Tablet0.26USD tablet
Mylan-Oxybutynin 5 mg Tablet0.26USD tablet
Novo-Oxybutynin 5 mg Tablet0.26USD tablet
Nu-Oxybutyn 5 mg Tablet0.26USD tablet
Pms-Oxybutynin 5 mg Tablet0.26USD tablet
Oxybutynin Chloride 5 mg/5ml Syrup0.21USD ml
Oxybutynin 5 mg tablet0.17USD tablet
Pms-Oxybutynin 2.5 mg Tablet0.14USD tablet
Pms-Oxybutynin 1 mg/ml Syrup0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2218714 No2005-08-232016-05-08Canada
US5164190 No1993-12-112010-12-11Us
US5674895 Yes1995-11-222015-11-22Us
US5840754 Yes1995-11-222015-11-22Us
US5912268 Yes1995-11-222015-11-22Us
US6262115 Yes1995-11-222015-11-22Us
US6743441 No2000-04-262020-04-26Us
US7029694 No2000-04-262020-04-26Us
US7081249 No2000-04-262020-04-26Us
US7081250 No2000-04-262020-04-26Us
US7081251 No2000-04-262020-04-26Us
US7081252 No2000-04-262020-04-26Us
US7179483 No2000-04-262020-04-26Us
US7198801 No2002-06-252022-06-25Us
US8241662 No2000-04-262020-04-26Us
US8920392 No2011-03-262031-03-26Us
US9259388 No2009-11-062029-11-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129-130 °CNot Available
logP4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP4.36ALOGPS
logP4.44ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)11.53ChemAxon
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity105.26 m3·mol-1ChemAxon
Polarizability41.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Baldwin CM, Keating GM: Transdermal oxybutynin. Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. [PubMed:19275276 ]
  4. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13. [PubMed:19446545 ]
  5. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  6. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678 ]
  7. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Dmochowski R: Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf. 2005;28(7):583-600. [PubMed:15963006 ]
  2. Nelson CP, Nahorski SR, Challiss RA: Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2006 Jan;316(1):279-88. Epub 2005 Sep 27. [PubMed:16188951 ]
  3. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13. [PubMed:19446545 ]
  4. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  5. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  4. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678 ]
  5. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Yaich M, Popon M, Medard Y, Aigrain EJ: In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics. 1998 Oct;8(5):449-51. [PubMed:9825837 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:14